Financials Shenzhen YHLO Biotech Co., Ltd.

Equities

688575

CNE100005204

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
23.98 CNY +0.13% Intraday chart for Shenzhen YHLO Biotech Co., Ltd. +6.63% +4.85%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 13,993 11,142 12,993 13,628 - -
Enterprise Value (EV) 1 13,993 11,142 12,993 13,628 13,628 13,628
P/E ratio 65.2 x 11 x 36.9 x 28.6 x 21.6 x 17.2 x
Yield 1.16% - - - - -
Capitalization / Revenue 11.9 x - 6.33 x 5.99 x 4.88 x 3.93 x
EV / Revenue 11.9 x - 6.33 x 5.99 x 4.88 x 3.93 x
EV / EBITDA - - 23.9 x 18.6 x 14 x 11.8 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 9.17 x - 5.08 x 4.62 x 3.86 x 3.33 x
Nbr of stocks (in thousands) 567,000 567,000 568,129 568,308 - -
Reference price 2 24.68 19.65 22.87 23.98 23.98 23.98
Announcement Date 2/18/22 2/27/23 2/23/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1,178 - 2,053 2,273 2,792 3,463
EBITDA 1 - - - 543.4 732.6 973.1 1,156
EBIT 1 - 226.8 - 340.5 524.5 699.6 836.5
Operating Margin - 19.26% - 16.59% 23.07% 25.05% 24.15%
Earnings before Tax (EBT) 1 - 227.8 - 330.1 521.1 695.2 831.7
Net income 1 210.5 204.7 - 358.4 476.3 630.3 792.6
Net margin - 17.38% - 17.46% 20.95% 22.57% 22.88%
EPS 2 0.4143 0.3786 1.780 0.6200 0.8375 1.108 1.397
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - 0.2857 - - - - -
Announcement Date 4/22/21 2/18/22 2/27/23 2/23/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1
Net sales 1 431.3
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 66.03
Net margin 15.31%
EPS -
Dividend per Share -
Announcement Date 4/19/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 17.2% 14.3% 15.4% 17.4% 18.6%
ROA (Net income/ Total Assets) - - 9.46% 11.6% 13.7% 14.8%
Assets 1 - - 3,789 4,106 4,600 5,355
Book Value Per Share 2 - 2.690 4.510 5.190 6.220 7.210
Cash Flow per Share 2 - 0.4600 -0.1300 1.210 1.250 1.550
Capex 1 - 373 663 410 370 477
Capex / Sales - 31.64% 32.28% 18.04% 13.25% 13.78%
Announcement Date 4/22/21 2/18/22 2/23/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
23.98 CNY
Average target price
28.67 CNY
Spread / Average Target
+19.55%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688575 Stock
  4. Financials Shenzhen YHLO Biotech Co., Ltd.